ESA聯(lián)合鐵劑治療腎性貧血的療效觀察及其對促紅素、亞鐵離子的影響

劉大鵬

[關(guān)鍵詞] 腎性貧血;ESA;蔗糖鐵;靜脈滴注;促紅素;亞鐵離子

[中圖分類號] R973.3;R556.3? ? ? ? ? [文獻標識碼] B? ? ? ? ? [文章編號] 1673-9701（2021）20-0040-03

Observation on the therapeutic efficacy of ESA combined with ferralium on renal anemia and its impacts on erythropoietin and ferrous ion

LIU Dapeng

General Ward， General Hospital of Fuxin Mining Bureau of Liaoning Health Industry Group，F(xiàn)uxin? ?123000，China

[Abstract] Objective To investigate the therapeutic efficacy of erythropoiesis-stimulating agents （ESA） combined with ferralium on renal anemia and its impacts on erythropoietin and ferrous ion levels in patients. Methods A total of 86 patients with renal anemia admitted to our hospital from January 2018 to January 2020 were selected as the research objects and divided into the study group and the control groupaccording to the random number table method，with 43 cases in each group. The study group was treated with ESA combined with iron sucrose intravenous drip， while the control group was treated with single ESA. The clinical efficacy， the hematocrit， hemoglobin， serum ferritin levels， and the incidence of adverse reactions of patients in the two groups were observed. Results The total effective rate of clinical treatment in the study group was 95.35%，which was higher than that of 76.74% in the control group，with statistically significant difference between the two groups （P<0.05）. Before treatment， the hematocrit， there was no statistically significant differences of hemoglobin and serum ferritin between the two groups （P>0.05）. After treatment， the hematocrit， hemoglobin， and serum ferritin levels of patients in the two groups were significantly higher than those before the treatment， with statistically significant differences（P<0.05）. Meanwhile， the hematocrit， hemoglobin and serum ferritin in the study group were higher than those in the control group，with statistically significant differences between the two groups（P<0.05）. After treatment，the total incidence of adverse reactions in the study group was 4.65%， which was lower than that of 20.93% in the control group， with statistically significant difference between the two groups（P<0.05）. Conclusion The treatment of renal anemia with ESA combined with iron sucrose preparation can effectively improve the clinical symptoms and blood environment， and promote the control of condition in patients.

[Key words] Renal anemia; Erythropoiesis-stimulating agents; Iron sucrose; Intravenous drip; Erythropoietin; Ferrous ion